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Therapeutic glucocorticoids prevent bone
loss but drive muscle wasting when
administered in chronic polyarthritis
C. G. Fenton1,2†, J. M. Webster2,4†, C. S. Martin2, S. Fareed2, C. Wehmeyer1, H. Mackie7, R. Jones3, A. P. Seabright9,
J. W. Lewis1,3, Y. C. Lai2,3,9, C. S. Goodyear7, S. W Jones1, M. S. Cooper5, G. G. Lavery2,4, R. Langen8, K. Raza1,6 and
R. S. Hardy1,2,3,10*
Abstract
Background: Patients with rheumatoid arthritis (RA) experience extra-articular manifestations including osteoporosis
and muscle wasting, which closely associate with severity of disease. Whilst therapeutic glucocorticoids (GCs) reduce
inflammation in RA, their actions on muscle and bone metabolism in the context of chronic inflammation remain
unclear. We utilised the TNF-tg model of chronic polyarthritis to ascertain the impact of therapeutic GCs on bone and
muscle homeostasis in the context of systemic inflammation.
Methods: TNF-tg and wild-type (WT) animals received either vehicle or the GC corticosterone (100 μg/ml) in drinking
water at onset of arthritis. Arthritis severity and clinical parameters were measured, serum collected for ELISA and
muscle and bone biopsies collected for μCT, histology and mRNA analysis. In vivo findings were examined in primary
cultures of osteoblasts, osteoclasts and myotubes.
Results: TNF-tg mice receiving GCs showed protection from inflammatory bone loss, characterised by a reduction
in serum markers of bone resorption, osteoclast numbers and osteoclast activity. In contrast, muscle wasting was
markedly increased in WT and TNF-tg animals receiving GCs, independently of inflammation. This was characterised
by a reduction in muscle weight and fibre size, and an induction in anti-anabolic and catabolic signalling.
Conclusions: This study demonstrates that when given in early onset chronic polyarthritis, oral GCs partially protect
against inflammatory bone loss, but induce marked muscle wasting. These results suggest that in patients with
inflammatory arthritis receiving GCs, the development of interventions to manage deleterious side effects in muscle
should be prioritised.
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Introduction
Patients with inflammatory arthritis experience extra-
articular manifestations, including osteoporosis and
muscle wasting, which closely correlate with measures of
disease activity [1–4]. Glucocorticoids (GCs) are effective
at controlling inflammation in rheumatoid arthritis (RA)
and are recommended as an initial line of therapy for the
rapid control of disease [5–7]. However, long-term GC
use is associated with osteoporosis and systemic muscle
wasting, resulting in increased fracture risk and mortality
in patients with RA [8–13].
It remains unclear what the effects of GCs on bone and
muscle are, when used to treat new onset inflammatory
arthritis, in particular, whether the beneficial effects of
controlling articular and systemic inflammation on bone
and muscle outweigh their direct catabolic actions in these
tissues.
Murine models of polyarthritis have proven a powerful
tool in examining the pathophysiology of inflammatory
diseases, such as RA. The TNF-tg mouse is a murine
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model of polyarthritis driven by the transgenic overex-
pression of the pro-inflammatory cytokine TNFα that
proved valuable in the initial validation of anti-TNFα bi-
ologicals [14]. We have previously shown that this ani-
mal model develops systemic bone loss and muscle
wasting in a manner consistent with human disease [15,
16]. In this study, we use the TNF-tg model of polyar-
thritis and wild-type (WT) counterparts to examine the
effects of orally administered anti-inflammatory GCs on
bone and muscle metabolism in the context of systemic
inflammation. We demonstrate that during active poly-
arthritis, therapeutic GCs are effective at suppressing
synovitis, joint destruction and systemic bone loss, but
markedly promote systemic muscle wasting.
Materials and methods
TNF-transgenic mouse model
Procedures on animals were performed under guidelines
by the Animal (Scientific Procedures) Act 1986 in accord-
ance with the project licence (P51102987) and approved
by the Birmingham Ethical Review Subcommittee
(BERSC). The TNF-tg model of chronic inflammatory
polyarthritis, obtained courtesy of Dr. George Kollias
(BSRC Fleming, Athens), were maintained on a C57BL/6
background and compared to WT littermates [17]. At day
32 of age, at the first onset of measurable polyarthritis,
male TNF-tg mice received drinking water supplemented
with either corticosterone (Cort) (100 μg/mL, 0.66% etha-
nol), or vehicle (0.66% ethanol) for 3 weeks. Interventions
were designed to model initial preventative bridging thera-
peutic glucocorticoid treatments in early onset disease.
Following the administration of vehicle and cortico-
sterone, mice were scored twice weekly for clinical scores
of disease activity and arthritic paw scores as previously
described [18, 19]. Mobility of animals within cages was
assessed by measuring numbers of rotations walked by an-
imals in a 3-min period and normalised to rotations per
minute to get an activity score. At day 53, serum was col-
lected by cardiac puncture under terminal anaesthesia,
and tissues excised for analysis. Wet tissue weights (mg)
of tibialis anterior, quadriceps and tibia were recorded,
normalised to total body weights and either snap frozen of
fixed in 4% formalin (mg).
Primary human osteoblast culture
Following ethical approval (UK National Research Ethics
Committee 14/ES/1044), patients with hip osteoarthritis
(OA) (age 69 ± 3 years, Kellgren Lawrence grade 3/4;
n = 4) were recruited prior to elective joint replacement
surgery. Trabecular chips of approximately 400–600mg
were excised and placed in PBS prior to culturing. Re-
agents were obtained from Sigma (Gillingham, UK) unless
otherwise stated. Trabecular bone chips from patient
samples were cultured in osteoclast growth media to fa-
cilitate release of osteoblasts (Additional file 1: Table S1).
Osteoblasts were allowed to grow and once confluent
bone chips were removed. Osteoblasts were then differen-
tiated in media containing TNFα (10 ng/ml) and/or corti-
sol (1000 ng/ml). Treatments were replaced three times
per week. Cultures were stained with 0.5% alizarin red S
to confirm differentiation into mature osteoblasts.
Primary human osteoclast culture
Peripheral blood mononuclear cells (PBMCs) from
healthy donors, obtained from the Scottish National Blood
Transfusion Service (approved by Glasgow NHS Trust-
East Ethics Committee), were isolated via Ficoll-paque
PLUS (GE Healthcare) density gradient centrifugation and
CD14+ monocytes isolated using positive selection
(Miltenyi). Monocytes were cultured in selective survival
media (Additional file 1: Table S1). Osteoclasts were gen-
erated using supplementation with1ng/ml RANKL over
72 h before stimulation with vehicle, 10 ng/ml TNFα or
1000 ng/ml corticosterone (or DMSO vehicle) as
appropriate. Osteoclast numbers were assessed by staining
with tartrate-resistant acid phosphatase (TRAP) kit
(Sigma-Aldrich). Osteoclast activity was assessed on
mineral-coated plates (Corning) at day 14. Images were
acquired using EVOS FL Auto Cell Imaging System (Life
Technologies). Osteoclasts were identified as TRAP +ve
multinucleated cells (nuclei ≥ 3). Resorption area was cal-
culated using Fiji software (ImageJ) and defined as % re-
sorbed area of entire well.
Primary murine muscle cell culture
Primary myotubes were generated from tibialis anterior
as previously described [20]. In brief, whole tibialis an-
terior muscle was removed from WT C57/Bl6 animals at
9 weeks and digested in type 1 collagenase at 37 °C for 2
h before isolation of individual fibres. Fibres were plated
in 2 ml of muscle expansion medium (Additional file 1:
Table S1) and grown in plates coated with Matrigel™
(Corning Life Sciences, Flintshire, UK) (diluted 1/40 in
DMEM High Glucose). Satellite cells migrating from
muscle fibres were removed and cultured in mainten-
ance medium until confluent, prior to differentiation in
selective media for 5 days (Additional file 1: Table S1).
Gene expression analysis
Gene expression in cells and tissues was assessed using
TaqMan® Gene Expression Assays (ThermoFisher
Scientific). Tissues were homogenised in liquid nitrogen
with a sterile pestle and mortar. mRNA was isolated
using an innuPREP RNA Mini Kit (Analytikjena,
Cambridge) as per the manufacturer’s instructions. One
microgramme of RNA per sample was reverse tran-
scribed using Multiscribe™ using the manufacturer’s
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protocol (ThermoFisher Scientific) to generate cDNA.
Alp, Bglap, Redd1, Foxo1, Trim63 and Fbxo32 were
determined using species-specific probe sets by real-
time PCR on an ABI7500 system (Applied Biosystems,
Warrington, UK). Final reactions are listed in Add-
itional file 1: Table S2. mRNA abundance was nor-
malised to that of 18S or GAPDH. Data were
obtained as Ct values and ΔCt determined (Ct target
– Ct 18S/GAPDH). Data were expressed as arbitrary
units (AU) using the following transformation: [arbi-
trary units (AU) = 1000 × (2−Δct)].
ELISA analysis
Serum IL-6 (R&D Systems, Abingdon, UK), P1NP and
CTX-1 (Immunodiagnostic Systems, Tyne & Wear, UK)
and conditioned media pro-collagen I α1 (R&D Systems,
Abingdon, UK) were determined using a commercially
available ELISA assays in accordance with the manufac-
turer’s instructions.
Histological analysis of joints and muscle
Histochemistry was performed on paraffin-embedded 10-
μm sections of hind paws and quadriceps of WT and
TNF-Tg animals following staining with haematoxylin and
eosin. Pannus size at the metatarsal-phalangeal joint inter-
face was determined using Image J software as previously
reported [18]. Sections were deparaffinised and incubated
in TRAP buffer (Additional file 1: Table S3) for 1 h at
37 °C to detect osteoclasts. Quantification of osteoclast
numbers on the bone surface pannus interface of the
ulna/humerus joint interface were normalised to bone sur-
face area determined by image J analysis of TRAP-stained
paraffin-embedded sections. Sections were stained with
H&E prior to quantitative analysis in order to visualise
pannus formation at the ankle joints and CSA of fibres.
For all quantifications, the mean of data from three adja-
cent 10-μm sections cut from the centre of the joint or
from the vastus medialis from six animals was utilised and
assessed using Image J software.
MicroCT morphometry analysis
Front paws and tibias from mice were imaged using a
Skyscan 1172 micro-CT scanner (Bruker) using X-ray
beam settings of 60 kV/167 μA with a 0.5-mm alumin-
ium filter. Projections were taken every 0.45° at 580-ms
exposure. Image volumes were reconstructed using the
Feldkamp algorithm (NRecon 1.6.1.5, Bruker) having ap-
plied beam hardening correction. Trabecular bone pa-
rameters (bone volume to tissue volume (BV/TV),
trabecular thickness (Tb.Th) and trabecular number
(Tb.N)) of the tibia were analysed using CTAn software.
One millimetre of bone (150 sections) in the metaphy-
seal region beneath the growth plate was analysed, and
regions of interest (ROI) were selected by drawing
around the trabecular network for each cross-sectional
slice. Front paws were reconstructed, and MeshLab 1.3.2
was used to generate meshes which could then be scored
for bone erosions as described previously [18].
Immunoblot analysis
Briefly, muscle were homogenised in 10-fold volume ex-
cess of ice-cold sucrose lysis buffer (Additional file 1:
Table S3). Protein concentration was determined using
the Bradford protein assay (ThermoScientific). Forty
microgrammes of protein was loaded into 4–12% Bis-
Tris midi protein gels (Invitrogen) prior to electrophor-
esis. Proteins were transferred and blocked in blocking
buffer (Additional file 1: Table S3) before incubation
with primary antibodies (Additional file 1: Table S4)
overnight at 4 °C. Membranes were then incubated in
horseradish peroxidase-conjugated secondary antibody
(1/10,000) at room temperature for 1 h. Antibody
detection was performed via enhanced chemilumines-
cence horseradish peroxidase substrate detection kit
(Millipore). Imaging was undertaken using a G:Box
Chemi-XR5 (Syngene) and band quantification via
(ImageJ). All data were corrected for protein loading as
determined after Ponceau S staining (Sigma-Aldrich).
Statistical analysis
Statistical significance was defined as P < 0.05 (*P < 0.05;
**P < 0.01; ***P < 0.001) using either an unpaired
Student’s t test or two way ANOVA with a Bonferroni
correction Tukey post hoc analysis where a Gaussian
distribution is identified.
Results
Oral GCs suppress disease activity in TNF-tg animals
TNF-tg mice received drinking water containing vehicle
or corticosterone at 100 μg/ml for 3 weeks. Daily oral
water intake of corticosterone was calculated per mouse
and was shown to be 22.0 ± 0.83 and 23.2 ± 2.0 μg/g body
weight/day and did not vary significantly between groups
(Additional file 2: Figure S1a). Serum corticosterone was
shown to be significantly elevated in both WTand TNF-tg
animals receiving corticosterone following oral intake rela-
tive to vehicle-treated controls (WT vehicle, 128.3 ± 66.7,
WT CORT, 456.2 ± 82.5 ng/ml; P < 0.005; TNF-tg vehicle,
119.8 ± 29.9, TNF-tg CORT, 485.1 ± 43.7 ng/ml; P < 0.005)
(Additional file 2: Figure S1b). Body weights did not
vary significantly between groups (Additional file 2:
Figure S1c). TNF-tg mice developed significant joint in-
flammation by day 53, characterised by increased joint de-
formity, redness and reduced mobility (clinical score, wild
type, 0.6 ± 0.004 vs TNF-tg, 6.2 ± 0.3; P < 0.005; joint in-
flammation, wild type, 0.16 ± 0.0001 vs TNF-tg, 7.2 ± 0.7;
P < 0.0001) (Fig. 1a, b). Corticosterone significantly re-
duced joint inflammation in TNF-tg animals (clinical
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score, TNF-tg/vehicle, 6.2 ± 0.3 vs TNF-tg/cort, 3.3 ± 0.9;
P < 0.005; joint inflammation, TNF-tg/vehicle, 6.2 ± 0.3 vs
TNF-tg/cort, 2.2 ± 0.4; P < 0.0005) (Fig. 1a, b) [21]. Scor-
ing of synovitis and joint erosions by histology and micro-
CT revealed a marked increase in vehicle-treated TNF-tg
mice relative to WT controls (Fig. 1c, d, e, g). These were
significantly abrogated in TNF-tg animals receiving cor-
ticosterone (joint erosion score, TNF-tg/vehicle, 13.6 ± 1.3
vs TNF-tg/cort, 5.3 ± 2.1; P < 0.0005, Pannus area,
TNF-tg/vehicle, 0.14 ± 3.9 vs TNF-tg/cort, 0.025 ± 0.004;
Fig. 1 a Clinical scoring (weight, inflammation, grimace, behaviour, mobility, inflammation severity and duration); b scoring of joint inflammation;
c quantification of cortical erosion (arbitrary units) in the bones of the ankle, metatarsals and phalanges; d representative images of 3D reconstructions
of hind paws using micro-CT; e histological scoring of synovitis (arbitrary units); f histological scoring (arbitrary units) of TRAP +ve osteoclast numbers
at the ulna/humerus joint interface; g representative images of synovitis at the ulna/humerus joint interface; h representative images of TRAP +ve
osteoclast numbers at the ulna/humerus joint interface; and i serum IL-6 levels determined by ELISA in WT and TNF-tg animals receiving either vehicle
or corticosterone (100 μg/mL) in drinking water over 3 weeks. Values are expressed as mean ± standard error of six animals per group. Statistical
significance was determined using two-way ANOVA with a Tukey post hoc analysis. Black arrows indicate sites of full-thickness cortical erosions.
*P < 0.05, **P < 0.005, ***P < 0.001
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P < 0.0005) (Fig. 1c, d, e, g). Juxta articular bone loss was
characterised by increased osteoclast numbers at the pan-
nus/subchondral bone interface (Fig 1f, h). Corticosterone
treatment reversed this, dramatically reducing osteoclast
numbers (TNF-tg/vehicle, 18 ± 3.3 vs TNF-tg/cort,
1.5 ± 0.2; P < 0.0005). Serum IL-6 was potently upregu-
lated in vehicle-treated TNF-tg animals and strongly sup-
pressed in animals receiving corticosterone. These data
demonstrate that corticosterone administered at 100 μg/
ml in drinking water over 3 weeks is sufficient to markedly
suppress disease activity and joint destruction.
Oral GCs prevent trabecular bone loss during polyarthritis
In vehicle-treated TNF-tg animals, significant trabecular
bone loss was apparent at day 53 (Fig. 2a). This appeared
to be partially abrogated in TNF-tg animal receiving cor-
ticosterone. Analysis of trabecular bone volume to tissue
volume (BV/TV), trabecular thickness (Tb.Th) and
trabecular number (Tb.N) was performed in all groups.
In vehicle-treated TNF-tg animals, a significant reduc-
tion in all parameters was apparent. Treatment with cor-
ticosterone partially protected from the loss in BV/TV
(BV/TV: TNF-tg/vehicle, 2.1% ± 0.21 vs TNF-tg/cortico-
sterone, 4.3% ± 0.23, P < 0.05) (Fig. 2b). Analysis of
Tb.Th in TNF-tg animals revealed a similar loss of tra-
becular thickness in those treated with either vehicle or
corticosterone (Tb.Th: TNF-tg/vehicle, 50.2 μm± 3.7 vs
TNF-tg/corticosterone, 50.6 μm± 2.7, NS) (Fig. 2c). In
contrast, corticosterone was able to protect against the
reduction in trabecular number in this model of in-
flammatory polyarthritis (Tb.N: TNF-tg/vehicle, 0.0004 1/
μm± 0.00002 vs TNF-tg/corticosterone, 0.00083 1/μm±
0.00002, P < 0.0001) (Fig. 2d). Together these data demon-
strate that oral administration of corticosterone provides
partial protection from inflammatory bone loss in TNF-tg
mice, characterised by preservation of trabecular number
but not thickness.
GCs suppress both bone formation and resorption during
inflammation
To delineate the actions of corticosterone on bone turn-
over in TNF-tg mice, we examined systemic markers of
bone formation (P1NP) and resorption (CTX-1) and mod-
elled therapeutic GC treatments in human cultures of os-
teoblasts and osteoclasts in combination with TNFα.
Whilst TNF-tg animals had significantly lower P1NP
levels at day 53 relative to WT counterparts, both groups
developed a comparable suppression of P1NP in response
Fig. 2 a Representative images of 3D reconstructions of tibia trabecular bone using micro-CT, b bone volume to tissue volume (BV/TV), c
trabecular thickness (Tb.Th) and d trabecular number (Tb.N) determined by Meshlab software analysis of micro CT in WT and TNF-tg animals receiving
either vehicle or corticosterone. Values are expressed as mean ± standard error of six animals per group. Statistical significance was determined using
two-way ANOVA with a Tukey post hoc analysis. *P < 0.05, **P < 0.005, ***P < 0.001. Black arrows indicate erosions
Fenton et al. Arthritis Research & Therapy          (2019) 21:182 Page 5 of 12
to corticosterone (wild type/vehicle, 494 ng/ml ± 46.3 vs
wild type/corticosterone, 31.3 ng/ml ± 8.2; P < 0.0001,
TNF-tg/vehicle, 269.7 ng/ml ± 27.2 vs TNF-tg/cortico-
sterone, 32.3 ng/ml ± 7.5; P < 0.0001) (Fig. 3a). Analysis of
mature osteoblast markers in tibia homogenates sup-
ported these data. Here, whilst gene expression of alkaline
phosphatase (Alp) and osteocalcin (Bglap) were signifi-
cantly reduced in TNF-tg animals at day 53 relative to
WT counterparts (Alp, 2.2-fold; Bglap, 2.6-fold; P <
0.0001), a comparable suppression of gene expression was
apparent in both groups receiving corticosterone relative
to vehicle (wild type, 32-fold; P < 0.0001, TNF-tg, 6-fold;
P < 0.0001) (Fig. 3b, c). In mature primary human osteo-
blasts, incubation with the pro-inflammatory cytokine
TNFα resulted in a significant reduction in both pro-
collagen production and osteocalcin mRNA (Fig. 3d, f ).
Fig. 3 a Serum P1NP (ng/ml) determined by ELISA. b, c Gene expression (AU) of Alp and Bglap, determined by RT qPCR in tibia homogenates, in WT
and TNF-tg animals receiving either vehicle or corticosterone (100 μg/mL) in drinking water over 3 weeks. d Representative image of primary human
pre-osteoblasts and mature nodule forming osteoblasts in vitro stained with alizarin red. e Pro-collagen 1 α1 formation determined by ELISA and f
quantification of gene expression (arbitrary units) of Bglap, determined by RT qPCR in primary cultures of mature osteoblasts treated with either
vehicle, TNFα (10 ng/ml), corticosterone (1 μmol/l) or a combination of TNF and corticosterone for 48 h. g Serum CTX-1 (ng/ml) determined by ELISA in
WT and TNF-tg animals receiving either vehicle or corticosterone. h TRAP +ve cells per well and i % calcified matrix resorption in primary human
osteoclasts cultures treated with either vehicle, TNFα (10 ng/ml), corticosterone (1 μmol/l) or a combination of TNFα and corticosterone over differentiation
from mononuclear cells. Values are expressed as mean ± standard error of six animals or primary cultures derived from six separate individuals. Statistical
significance was determined using either two-way or one-way ANOVA with Tukey post hoc analysis. *P< 0.05, **P< 0.005, ***P< 0.001
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Here, the addition of the GC cortisol resulted in a com-
parable and dramatic suppression of osteoblast matrix for-
mation and mRNA expression in control and TNFα-
treated osteoblasts (pro-collagen Iα1, control, 524 ng/ml ±
128.9 vs cortisol, 50.0 ng/ml ± 93.1, P < 0.001, TNFα,
158.2 ng/ml ± 131.4 vs TNFα/cortisol, 11.3 ng/ml ± 6.8;
P < 0.001; BGLAP, control vs cortisol, 43-fold suppression;
P < 0.001, TNFα vs TNFα/cortisol; 10-fold suppression;
P < 0.05).
Serum CTX-1 levels were determined as a measure of
osteoclastic bone resorption. TNF-tg animals receiving cor-
ticosterone had a significant suppression of CTX-1 at day
53 (TNF-tg/vehicle, 87.6 ng/ml ± 11.3 vs TNF-tg/cortico-
sterone, 36.3 ng/ml ± 3.1; P < 0.05) (Fig. 3g). In primary hu-
man osteoclasts, the addition of cortisol to TNFα-
stimulated cultures resulted in a significant suppression of
both osteoclast numbers and calcified matrix resorption in
vitro (osteoclast no., TNFα, 297.5 cells per well ± 53.7 vs
TNFα/cortisol, 85.6 cells per well ± 17.8; P < 0.05; resorbed
area, TNFα, 32.5% ± 7.0 vs TNFα/cortisol, 2.1% ± 0.8;
P < 0.05) (Fig. 3h, i). The resorption pits in wells treated
with cortisol were characterised by a reduction in both
number and size (Additional file 3: Figure S2a). These data
indicate that GCs suppress both osteoblast bone forma-
tion and osteoclast maturation and activity.
Oral GCs drive severe muscle wasting and reduce
mobility in TNF-tg animals
We examined muscle weights and morphology in WTand
TNF-tg animals receiving corticosterone. Corticosterone
significantly reduced quadriceps and tibialis anterior
weights in WT and TNF-tg animals relative to vehicle
controls (quadriceps, wild type/vehicle, 0.0029mg/body
weight ± 0.00024 vs wild type/corticosterone, 0.0019mg/
body weight ± 0.00021; P < 0.0001; TNF-tg/vehicle,
0.0025.7mg/body weight ± 0.00025 vs TNF-tg/cortico-
sterone, 0.0017mg/body weight ± 0.00028; P < 0.001)
(Fig. 4a, b). Analysis of animal mobility with cages was
assessed at day 53 to determine the effects of polyarthritis
and corticosterone treatment (Fig. 4c). Here, a significant
reduction in movement was apparent in TNF-tg animals
relative to WT counterparts. This was mirrored by a
comparable reduction in movement seen in both WT and
TNF-tg animals receiving corticosterone relative to
vehicle-treated WT counterparts. Analysis of average
muscle fibre cross-sectional area (CSA) indicated that this
was underpinned by a reduction in muscle fibre size in
WT and TNF-tg animals receiving corticosterone (fibre
size, wild type/vehicle, 2064 μm2 ± 144 vs wild type/cor-
ticosterone, 1636 μm2 ± 96; P < 0.05; TNF-tg/vehicle,
1767 μm2 ± 76 vs TNF-tg/corticosterone, 1559 μm2 ± 88;
P < 0.05) (Fig. 4c–e). Further analysis of fibre CSA distri-
bution identified a significant shift towards increased
small diameter fibres in TNF-tg animals relative to WT
counterparts (Fig. 4e). In response to corticosterone, both
WT and TNF-tg animals demonstrated a further shift in
fibre CSA distribution, favouring a significant increase in
small fibres (800–1800 μm2) and significant reduction in
large fibres (2200–2600 μm2) relative to vehicle-treated
controls (Fig. 4f, g). In contrast, no significant shift was
observed between WT and TNF-tg animals receiving cor-
ticosterone (Fig 4h). These data demonstrate that during
active polyarthritis, administration of oral corticosterone
promotes muscle wasting independent of inflammation.
During inflammation, oral GCs drive catabolic and anti-
anabolic muscle wasting
To ascertain the pathways that underpin increased muscle
wasting in TNF-tg mice treated with GCs, we examined
well-defined catabolic and anti-anabolic signalling
pathways in tibialis anterior muscle homogenates and in
primary muscle cultures. In wild-type animals, cortico-
sterone resulted in a comparable induction in expression
of the anti-anabolic gene Redd1 and the catabolic genes
Foxo1, Trim63 and Fbxo32 (Redd1, 7.7-fold; P < 0.005;
Foxo1, 10.3-fold; P < 0.0005; Trim63, 7.8-fold; P < 0.05;
Fbxo32, 8.9-fold; P < 0.0005) (Fig. 5a–d). Comparable in-
ductions in gene expression of Foxo1, Trim63 and Fxo32
were also apparent in TNF-tg animals receiving cortico-
sterone (Foxo1, 3.1; P < 0.005, Trim63, 3.2-fold; P < 0.05;
Fbxo32, 5.2-fold; P < 0.0005) (Fig. 5b–d, Additional file 4:
Figure S3). These results were supported by a marked in-
crease in protein expression of both phosphorylated and
total Foxo1 in WTand TNF-tg animals in response to cor-
ticosterone (Fig. 5j). In contrast, expression of anabolic
factors such as EF2 did not differ between groups. A dee-
per analysis of muscle gene expression was performed
examining catabolic signalling and E3 ligases (Foxo1,
Fbxo32, Trim63, Ube3a), anabolic and anti-anabolic myo-
kines and signalling (Igf1, Igf2, Mstn, Redd1), muscle dif-
ferentiation (Myog, MyoD, Myf5, Myf6) and inflammatory
myokines and signalling (Tnfa, Il6, Cxcl1, IkBa) (Add-
itional file 3: Figure S2a-p). In addition to the upregulation
of all atrogenes examined, gene expression of the inflam-
matory myokines Il6 and Cxcl1 showed evidence of sup-
pression in response to corticosterone in line with
expected anti-inflammatory action. Similar observations
were apparent in primary cultures of murine muscle cells
treated with corticosterone. Here, a significant upregula-
tion was observed in Trim63 and Fbxo32 regardless of in-
flammatory stimulation with TNFα (Fig. 5e–i). These data
demonstrate that at therapeutic doses, GCs result in a sig-
nificant induction in anti-anabolic and catabolic gene ex-
pression in muscle.
Discussion
We employed a murine model of polyarthritis treated
with oral corticosterone to examine the effects of GCs
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on bone and muscle in the context of initial preventative
bridging therapy in early-onset polyarthritis. This ap-
proach was effective at suppressing disease activity and
joint destruction and has previously been demonstrated
to mimic the kinetics of oral GC therapy [22]. Clinically,
GCs suppress disease activity, joint destruction and sys-
temic inflammation, which are drivers of bone and
muscle loss in RA [1, 23–26]. However, whilst effective
in controlling disease activity, they are independently as-
sociated with GC-induced osteoporosis and muscle
wasting through direct anti-anabolic and catabolic path-
ways [8–13, 27, 28]. Currently, their impact on bone and
muscle when used to treat new-onset inflammatory arth-
ritis remains unclear.
The anti-inflammatory properties of oral GC adminis-
tration were evidenced by a marked suppression in
disease activity, joint inflammation and joint destruction
in the TNF-tg model. We observed a marked decrease in
trabecular bone volume at day 53 in TNF-tg mice, char-
acterised by an increase in osteoclast activity and num-
bers. Administration of oral GCs resulted in a significant
protection from this inflammatory bone loss.
Increased osteoclast numbers and activity are recog-
nised mediators of inflammatory bone loss in RA, whilst
therapeutic control of inflammation abrogates this [29–
31]. Our study mirrors these findings, where TRAP +ve
osteoclast numbers and bone resorption determined by
serum CTX1 were significantly reduced in animals re-
ceiving corticosterone. In vitro data supported these
findings where osteoclast numbers and activity were
markedly reduced by GCs in TNFα-stimulated osteo-
clasts. These data indicate that the protection from
Fig. 4 a, b Total quadriceps and tibialis anterior muscle weights relative to total bodyweight, c mouse activity determined by rotations of cage
per minute, d average quadriceps muscle fibre cross sectional area (μm2), e representative images of quadriceps muscle sections, f–i distribution
of quadriceps muscle fibre cross-sectional area determined using Image J in paraffin embedded sections in WT and TNF-Tg animals receiving either
vehicle or corticosterone (100 μg/mL) in drinking water over 3 weeks. Values are expressed as mean ± standard error of six animals per group.
Statistical significance was determined using two-way ANOVA with a Tukey post hoc analysis. *P < 0.05, **P < 0.005, ***P < 0.001 (scale bars, 50 μm)
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inflammatory bone loss in TNF-tg animals receiving cor-
ticosterone are mediated through the suppression of
osteoclastic bone resorption.
Both inflammation and GCs are reported to be
negative regulators of bone formation and osteo-
blastogenesis [32–34]. Here, the anti-anabolic actions
of GCs on bone formation are associated with a rapid
suppression of P1NP and reduction in trabecular bone
in patients [34].
In our study, whilst markers of mature osteoblasts and
bone formation were suppressed in TNF-tg animals,
therapeutic GCs dramatically exacerbated this and mir-
ror observations in patient studies. These data suggest
that the direct anti-anabolic actions of GCs outweigh
Fig. 5 a–d Quantification of gene expression (arbitrary units) of Redd1, Foxo1, Trim63 and Fbxo32, determined by RT qPCR, in ex vivo quadriceps
biopsies. e–h Representative images of primary murine myoblast and myotubes and quantification of gene expression of Redd1, Foxo1, Trim63 and
Fbxo32, determined by RT qPCR and j representative western blot staining for p-Foxo1, total Foxo1, pEF2 and p-EF2 after loading of 20 μg of protein
and normalisation to ponso staining in quadriceps for either WT mice and TNF-Tg animals receiving either vehicle or corticosterone (100 μg/mL) in
drinking water over 3 weeks or in primary myotubes treated with either vehicle, TNFα (10 ng/ml), corticosterone (1 μmol/l) or a combination of TNF
and corticosterone for 48 h. Values are expressed as mean ± standard error of six animals or primary cultures derived from four separate animals.
Statistical significance was determined using two-way ANOVA with a Tukey post hoc analysis. *P < 0.05, **P < 0.005, ***P < 0.001
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positive effects of suppressing inflammation on bone for-
mation in vivo.
Several studies have explored the effects of therapeutic
GCs on bone metabolism in RA. These yielded conflict-
ing outcomes and are complicated by differences in dis-
ease severity, parallel DMARD therapy and dosing of
GCs. Several reported increased fracture risk, with com-
plications more apparent at higher doses [23, 35–37].
Others reported no worsening of bone mineral density
or fracture risk when given at low doses in combination
with DMARDS [3, 38, 39].
In contrast to bone loss, oral GCs increased muscle
wasting and did not restore animal mobility in the TNF-
tg model of polyarthritis, despite effective suppression of
disease activity. This was characterised by a comparable
decrease in muscle wet weights and fibre size in WT and
TNF-tg animals suggesting that these changes occur in-
dependent of inflammatory muscle wasting and that
GC-driven muscle wasting impacts on animal mobility.
In patients receiving therapeutic GCs, muscle wasting
is characterised by increased protein breakdown driven
through the ubiquitin proteasome and the lysosomal sys-
tems [11–13, 28]. Our results mirror this with an upreg-
ulation of anti-anabolic and catabolic pathway activation
in animals receiving corticosterone.
Similar results were observed in primary muscle cul-
tures, where regardless of pro-inflammatory stimulation
with TNFα, a direct induction of catabolic gene expression
was observed in response to GCs. Additive or synergistic
catabolic actions in muscle by oral GCs in combination
with inflammation were not observed in this study. This is
most likely attributed to the effective suppression of well-
defined inflammatory mediators of muscle wasting that
are themselves suppressed by GCs [40–42].
Few studies address therapeutic GC use on muscle
wasting in RA. However, of note, a recent study by Lem-
mey et al. reported a rapid loss of muscle mass in RA
patients receiving a single intramuscular injection of
GCs to treat disease flares [43]. Unfortunately, this study
was not able to address the impact of disease activity (it-
self a significant driver of muscle wasting) and DMARD
use on muscle wasting independent of corticosterone
use. However, our study supports the author’s conclu-
sions that muscle wasting is an immediate and severe
complication in RA patients receiving GCs, independent
of inflammation. Indeed, the marked increase in fracture
risk upon initiation of GCs in RA may be primarily
driven by GC-induced muscle wasting, rather than sec-
ondary to GC-induced osteoporosis [44].
Conclusions
Using an animal model of chronic polyarthritis, this
study examined how controlling disease activity with
oral GCs as a monotherapy influenced inflammatory
osteoporosis and muscle wasting. We demonstrate that
when given in early disease, oral GCs protect against in-
flammatory bone loss, but induce marked systemic
muscle wasting. These results suggest that the develop-
ment of interventions to manage deleterious side effects
in muscle should be prioritised in patients with inflam-
matory arthritis receiving GCs.
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